Pertussis toxin-sensitive secretory phospholipase A2 expression and motility in activated primary human keratinocytes

Krystyna E. Rys-Sikora, Alice P. Pentland, Raymond L. Konger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Secretory phospholipase A2 and cycloxygenase-2 are coexpressed in activated primary keratinocytes. These proteins are known to be functionally linked, mediating proliferation of human keratinocytes during epidermal wound repair. Primary human keratinocytes grown at low densities (15-30%; nonconfluent) produce high levels of prostaglandin E2 important for proliferation and are a good model for studying activated keratinocytes after injury. In this study, we used this model to assess the role of secretory phospholipase A2 and cycloxygenase-2 in keratinocyte motility. Initial work showed 24 h pretreatment with 20 ng pertussis toxin per ml, an inhibitor of the inhibitory G-protein, decreased prostaglandin E2 production and both secretory phospholipase A2 and cycloxygenase-2 protein expression. This suggested that inhibitory G-protein may be involved in mediating expression of these proteins. Pertussis toxin also caused changes in cell morphology, actin organization, and keratinocyte motility. Pretreatment with 5 μM 12-epi-scalaradial, a secretory phospholipase A2 inhibitor, caused similar changes in cell motility and actin organization; however, the specific cycloxygenase-2 inhibitor, SC-58236 (20 nM) was much less effective. These results suggested that secretory phospholipase A2 plays a part in keratinocyte motility that is independent of its functional linkage to cycloxygenase-2 and prostaglandin E2 biosynthesis.

Original languageEnglish (US)
Pages (from-to)86-95
Number of pages10
JournalJournal of Investigative Dermatology
Volume120
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Secretory Phospholipase A2
Pertussis Toxin
Keratinocytes
Dinoprostone
GTP-Binding Proteins
Actins
Proteins
Biosynthesis
Wounds and Injuries
Cell Movement
Repair

Keywords

  • Cyclooxygenase-2/G-proteins/Migration/Phospholipases A/Wounds

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Pertussis toxin-sensitive secretory phospholipase A2 expression and motility in activated primary human keratinocytes. / Rys-Sikora, Krystyna E.; Pentland, Alice P.; Konger, Raymond L.

In: Journal of Investigative Dermatology, Vol. 120, No. 1, 01.01.2003, p. 86-95.

Research output: Contribution to journalArticle

@article{b37cfabbc4854cd4b8337aec97a4441d,
title = "Pertussis toxin-sensitive secretory phospholipase A2 expression and motility in activated primary human keratinocytes",
abstract = "Secretory phospholipase A2 and cycloxygenase-2 are coexpressed in activated primary keratinocytes. These proteins are known to be functionally linked, mediating proliferation of human keratinocytes during epidermal wound repair. Primary human keratinocytes grown at low densities (15-30{\%}; nonconfluent) produce high levels of prostaglandin E2 important for proliferation and are a good model for studying activated keratinocytes after injury. In this study, we used this model to assess the role of secretory phospholipase A2 and cycloxygenase-2 in keratinocyte motility. Initial work showed 24 h pretreatment with 20 ng pertussis toxin per ml, an inhibitor of the inhibitory G-protein, decreased prostaglandin E2 production and both secretory phospholipase A2 and cycloxygenase-2 protein expression. This suggested that inhibitory G-protein may be involved in mediating expression of these proteins. Pertussis toxin also caused changes in cell morphology, actin organization, and keratinocyte motility. Pretreatment with 5 μM 12-epi-scalaradial, a secretory phospholipase A2 inhibitor, caused similar changes in cell motility and actin organization; however, the specific cycloxygenase-2 inhibitor, SC-58236 (20 nM) was much less effective. These results suggested that secretory phospholipase A2 plays a part in keratinocyte motility that is independent of its functional linkage to cycloxygenase-2 and prostaglandin E2 biosynthesis.",
keywords = "Cyclooxygenase-2/G-proteins/Migration/Phospholipases A/Wounds",
author = "Rys-Sikora, {Krystyna E.} and Pentland, {Alice P.} and Konger, {Raymond L.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1046/j.1523-1747.2003.12001.x",
language = "English (US)",
volume = "120",
pages = "86--95",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Pertussis toxin-sensitive secretory phospholipase A2 expression and motility in activated primary human keratinocytes

AU - Rys-Sikora, Krystyna E.

AU - Pentland, Alice P.

AU - Konger, Raymond L.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Secretory phospholipase A2 and cycloxygenase-2 are coexpressed in activated primary keratinocytes. These proteins are known to be functionally linked, mediating proliferation of human keratinocytes during epidermal wound repair. Primary human keratinocytes grown at low densities (15-30%; nonconfluent) produce high levels of prostaglandin E2 important for proliferation and are a good model for studying activated keratinocytes after injury. In this study, we used this model to assess the role of secretory phospholipase A2 and cycloxygenase-2 in keratinocyte motility. Initial work showed 24 h pretreatment with 20 ng pertussis toxin per ml, an inhibitor of the inhibitory G-protein, decreased prostaglandin E2 production and both secretory phospholipase A2 and cycloxygenase-2 protein expression. This suggested that inhibitory G-protein may be involved in mediating expression of these proteins. Pertussis toxin also caused changes in cell morphology, actin organization, and keratinocyte motility. Pretreatment with 5 μM 12-epi-scalaradial, a secretory phospholipase A2 inhibitor, caused similar changes in cell motility and actin organization; however, the specific cycloxygenase-2 inhibitor, SC-58236 (20 nM) was much less effective. These results suggested that secretory phospholipase A2 plays a part in keratinocyte motility that is independent of its functional linkage to cycloxygenase-2 and prostaglandin E2 biosynthesis.

AB - Secretory phospholipase A2 and cycloxygenase-2 are coexpressed in activated primary keratinocytes. These proteins are known to be functionally linked, mediating proliferation of human keratinocytes during epidermal wound repair. Primary human keratinocytes grown at low densities (15-30%; nonconfluent) produce high levels of prostaglandin E2 important for proliferation and are a good model for studying activated keratinocytes after injury. In this study, we used this model to assess the role of secretory phospholipase A2 and cycloxygenase-2 in keratinocyte motility. Initial work showed 24 h pretreatment with 20 ng pertussis toxin per ml, an inhibitor of the inhibitory G-protein, decreased prostaglandin E2 production and both secretory phospholipase A2 and cycloxygenase-2 protein expression. This suggested that inhibitory G-protein may be involved in mediating expression of these proteins. Pertussis toxin also caused changes in cell morphology, actin organization, and keratinocyte motility. Pretreatment with 5 μM 12-epi-scalaradial, a secretory phospholipase A2 inhibitor, caused similar changes in cell motility and actin organization; however, the specific cycloxygenase-2 inhibitor, SC-58236 (20 nM) was much less effective. These results suggested that secretory phospholipase A2 plays a part in keratinocyte motility that is independent of its functional linkage to cycloxygenase-2 and prostaglandin E2 biosynthesis.

KW - Cyclooxygenase-2/G-proteins/Migration/Phospholipases A/Wounds

UR - http://www.scopus.com/inward/record.url?scp=0037243525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037243525&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1747.2003.12001.x

DO - 10.1046/j.1523-1747.2003.12001.x

M3 - Article

C2 - 12535202

AN - SCOPUS:0037243525

VL - 120

SP - 86

EP - 95

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 1

ER -